GeneOne Life Science, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GeneOne Life Science, Inc.
South Korea is stepping on the gas to develop its own mRNA COVID-19 vaccine and eventually next generation mRNA platform technology for use in other diseases, to meet its goal of becoming a global vaccine hub.
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
Plus: Humainigen announced data from its still-blinded Phase III trial, while Korea's GeneOne advanced a DNA vaccine candidate.
- Contract Research, Toxicology Testing-CRO
- Consulting Services
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- VGXI, Inc.